CDK4/6 Inhibitor Bireociclib Improves Progression-Free Survival in Advanced Breast Cancer

The addition of bireociclib (Xuanyuening; Xuanzhu Biopharm) to fulvestrant (FALSODEX; AstraZeneca) nearly doubled median progression-free survival (PFS) compared with fulvestrant alone in patients with hormone receptor (HR)–positive, HER2-negative advanced breast cancer (ABC) who had progressed on prior endocrine therapy. These are the final findings of the BRIGHT-2 phase 3 randomized clinical trial, the results of which were published in JAMA Oncology.¹ With roughly 11 months of additional follow-up beyond the interim analysis, the results reinforce and extend bireociclib's clinical value as a CDK4/6 inhibitor (CDK4/6i) in this patient population.

BRIGHT-2 was a double-blind, placebo-controlled phase 3 trial conducted at 64 hospitals in China, enrolling 305 patients. Patients were randomized 2:1 to receive either bireociclib (360 mg orally every 12 hours) plus fulvestrant (500 mg intramuscularly) or placebo plus fulvestrant. The primary end point was investigator-assessed PFS and secondary end points included overall survival (OS), objective response rate (ORR), and duration of response. The median (IQR) follow-up at data cutoff was 19 (18.5-19.6) months. Patients had a mean (SD) age of 54.1 (10.2) years, and 87.9% had received prior systemic chemotherapy.

The bireociclib group achieved a median PFS of 14.7 months compared with 7.3 months in the placebo group (HR, 0.54; 95% CI, 0.40–0.74; P < .001). These findings were consistent when assessed by blinded independent central review, which showed an even more favorable HR of 0.47. ORR in patients with measurable disease reached 50.3% with bireociclib vs 16.7% with placebo. These figures exceed historical benchmarks from comparable trials, including MONARCH-2 (NCT02107703), MONALEESA-3 (NCT02422615), and PALOMA-3 (NCT05388669).

Subgroup analyses revealed particularly strong PFS benefits in several high-risk populations. These included patients with primary endocrine resistance (HR, 0.34), a disease-free interval of 24 months or less (HR, 0.30), bone-only metastases (HR, 0.18), and pre- or perimenopausal status (HR, 0.40). Patients harboring ESR1, PIK3CA, or TP53 alterations that are frequently seen in endocrine-resistant ABC associated with poorer prognosis and limited treatment options also showed consistent PFS improvement.

Another interesting finding was an exploratory association between early-onset diarrhea and improved outcomes. As the authors note, "onset of diarrhea within 7 days of bireociclib initiation was associated with longer PFS among patients taking bireociclib." This represents a potentially meaningful clinical signal, although one that warrants prospective validation given its post hoc nature.

The most common adverse events were diarrhea (92.6%), neutropenia (89.2%), and grade 1 or 2 leukopenia (86.8%). Grade 3 or higher neutropenia occurred in 33.3% of patients. Importantly, dose reduction did not appear to compromise efficacy, and permanent treatment discontinuation due to adverse events occurred in only 4.4% of patients.

CDK4/6 inhibitors are the backbone of second-line therapy for HR-positive, HER2-negative ABC after endocrine progression, with established agents including palbociclib, ribociclib, and abemaciclib demonstrating PFS and, in some cases, OS benefits.² Bireociclib's approximately 18-fold greater selectivity for CDK4 over CDK6, plus additional activity against CDK2 and CDK9, may offer both tolerability and efficacy advantages, though head-to-head trials are needed to confirm any comparative benefits. The drug was approved in China in May 2025, expanding CDK4/6 inhibitor options in a region where drug availability and sequencing flexibility remain important clinical considerations.

OS data are still immature, and longer follow-up will be necessary to determine whether the PFS benefit translates to a survival advantage. Future research should also clarify the clinical relevance of early diarrhea as a potential pharmacodynamic marker, and prospective biomarker studies could help identify which patients benefit most.

The authors concluded that "the findings of this randomized clinical trial provide valuable evidence on the efficacy and safety of bireociclib plus fulvestrant in patients with HR-positive, [HER2]-negative ABC in Chinese clinical practice and supports the potential for individualized treatment strategies in specific subgroups."

With a broad and consistent PFS benefit across clinically relevant subgroups, including those with primary resistance and high-risk molecular features, bireociclib adds meaningful depth to the CDK4/6i treatment landscape. As OS data mature and real-world experience accumulates, its role in sequencing strategies will come into clearer focus.

References

1.Wang J, Zhang Q, Li H, et al. Bireociclib plus fulvestrant in advanced breast cancer after endocrine progression: the BRIGHT-2 phase 3 randomized clinical trial. JAMA Oncol. Published online March 19, 2026. doi:10.1001/jamaoncol.2026.0318

2.Braal CL, Jongbloed EM, Wilting SM, Mathijssen RHJ, Koolen SLW, Jager A. Inhibiting CDK4/6 in breast cancer with palbociclib, ribociclib, and abemaciclib: similarities and differences. Drugs. 2021;81(3):317–331. doi:10.1007/s40265-020-01461-2